IP Library Granted Patent US 10,765,692
Granted Patent B2
US 10,765,692 · App. 16/663,743 · Granted Sep 8, 2020

Maribavir isomers, compositions, methods of making and methods of using

Inventor: John D. Peabody, III (West Chester, PA)
Assignee: Shire Viropharma Incorporated
A61K31/7056A61K45/06G01N33/94G09B19/00G01N2430/00G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,765,692
App. No.
16/663,743
Granted
Sep 8, 2020
Kind
B2
Abstract

The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.

Claims (9)

1. A composition comprising maribavir and at least one of an antacid which is effective for neutralizing acid that catalyzes isomerization of maribavir, (ii) an antibiotic having activity against a microorganism that mediates isomerization of maribavir, or (iii) an antagonist that inhibits metabolism that induces isomerization of maribavir, said isomerization producing a decrease in the therapeutic efficacy of maribavir.

2. The composition of claim 1 , wherein said composition comprises maribavir and an antacid which is effective for neutralizing acid that catalyzes isomerization of maribavir.

3. The composition of claim 1 , wherein said composition comprises maribavir and an antibiotic having activity against a microorganism that mediates isomerization of maribavir.

4. The composition of claim 1 , wherein said composition comprises maribavir and an antagonist that inhibits metabolism that induces isomerization of maribavir, said isomerization producing a decrease in the therapeutic efficacy of maribavir.

5. The composition of claim 1 , wherein said composition comprises at least 100 mg of maribavir.

6. The composition of claim 5 , wherein said composition comprises up to 3200 mg of maribavir.

7. The composition of claim 1 , wherein said composition is an immediate release formulation, a delayed release formulation, a controlled release formulation or an intravenous formulation.

8. The composition of claim 1 , wherein said composition is formulated for oral administration.

9. The composition of claim 1 , wherein said composition is formulated for intravenous administration.

Assignments (4)
CHANGE OF NAME Recorded Jun 15, 2021
From: SHIRE VIROPHARMA INCORPORATED
To: SHIRE VIROPHARMA LLC
Reel/Frame 056596/0380 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2021
From: SHIRE VIROPHARMA LLC
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056307/0254 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2020
From: PEABODY, JOHN D., III
To: VIROPHARMA INCORPORATED
Reel/Frame 052661/0324 →
CHANGE OF NAME Recorded May 14, 2020
From: VIROPHARMA INCORPORATED
To: SHIRE VIROPHARMA INCORPORATED
Reel/Frame 052661/0371 →
Continuity (6)
Division 15291639 · Oct 12, 2016
Division 15055043 · Feb 26, 2016
Continuation 14595548 · Jan 13, 2015
Continuation 13282501 · Oct 27, 2011
Provisional Application 61407637 · Oct 28, 2010
Related Publication 20200054658A1 · Feb 20, 2020
Cited By (2)
US 12,447,169 US 12,661,368